<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520569</url>
  </required_header>
  <id_info>
    <org_study_id>19948</org_study_id>
    <secondary_id>T32DK007646</secondary_id>
    <nct_id>NCT03520569</nct_id>
  </id_info>
  <brief_title>Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults</brief_title>
  <official_title>Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying the effects of Hyperglycemia on vascular function and insulin
      sensitivity on healthy adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study 22 healthy subjects (18-35 yrs) four times as follows:

        1. Saline + Octreotide + euglycemia;

        2. Octreotide + hyperglycemia;

        3. Octreotide + hyperglycemia + insulin clamp and

        4. Octreotide + Euglycemia + insulin clamp.

      The sequence of admissions will be assigned randomly. The investigators will assess function
      in conduit (pulse wave velocity-PWV, augmentation index-AI and flow-mediated dilation-FMD),
      resistance (post-ischemic flow velocity-PIFV) and heart and skeletal muscle microvascular
      (contrast enhanced ultrasound-CEU) vessels.

      This work will:

      a) identify whether vascular stiffness and indices of NO action are impaired throughout the
      arterial tree with hyperglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each subject is studied 4 times in a randomized sequential order</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp</measure>
    <time_frame>baseline and after 2 hour insulin clamp</time_frame>
    <description>Vascular measure of conduit artery stiffness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Augmentation Index between baseline and after 2 hour insulin clamp</measure>
    <time_frame>baseline and after 2 hour insulin clamp</time_frame>
    <description>Measurement of central artery stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Wave Velocity (PWV) between baseline and after 2 hour insulin clamp</measure>
    <time_frame>baseline and after 2 hour insulin clamp</time_frame>
    <description>Measurement of central artery stiffness</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Vascular Stiffness</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Octreotide- Euglycemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide - Euglycemia- insulin clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide- hyperglycemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide- hyperglycemia - insulin clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>we are using it to block insulin secretion from the pancreas</description>
    <arm_group_label>Octreotide- Euglycemia</arm_group_label>
    <arm_group_label>Octreotide - Euglycemia- insulin clamp</arm_group_label>
    <arm_group_label>Octreotide- hyperglycemia</arm_group_label>
    <arm_group_label>Octreotide- hyperglycemia - insulin clamp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp</description>
    <arm_group_label>Octreotide- Euglycemia</arm_group_label>
    <arm_group_label>Octreotide - Euglycemia- insulin clamp</arm_group_label>
    <arm_group_label>Octreotide- hyperglycemia</arm_group_label>
    <arm_group_label>Octreotide- hyperglycemia - insulin clamp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose 20% solution</intervention_name>
    <description>We are using dextrose to maintain glycemia level</description>
    <arm_group_label>Octreotide- Euglycemia</arm_group_label>
    <arm_group_label>Octreotide - Euglycemia- insulin clamp</arm_group_label>
    <arm_group_label>Octreotide- hyperglycemia</arm_group_label>
    <arm_group_label>Octreotide- hyperglycemia - insulin clamp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy with no chronic illness

          -  Age 18-35

          -  Normal BMI (18-25)

          -  Normal screening labs or no clinically significant values

        Exclusion Criteria:

          -  First degree relative with Type 2 Diabetes

          -  Smoking presently or in the past 6 months

          -  Medications that affect the vasculature

          -  Overweight or other indications of insulin resistance

          -  Elevated LDL cholesterol &gt; 160

          -  Elevated BP &gt; 140/90

          -  History of congestive heart failure, ischemic heart disease, severe pulmonary disease,
             liver or kidney disease, bleeding disorders

          -  Any vascular disease such as myocardial infarction, stroke, peripheral vascular
             disease

          -  Presence of an intracardiac or intrapulmonary shunt (we will screen for this by
             auscultation during the physical exam by PI).

          -  Pregnant or breastfeeding.

          -  Known hypersensitivity to perflutren (contained in Definity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eugene J. Barrett, MD PhD</last_name>
    <phone>434-924-1263</phone>
    <email>ejb8x@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Hartline, MEd</last_name>
    <phone>434-984-5247</phone>
    <email>lmh9d@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene J. Barrett, MD PhD</last_name>
      <phone>434-924-1263</phone>
      <email>ejb8x@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zhenqi Liu</last_name>
      <phone>434-243-2603</phone>
      <email>ZL3e@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eugene J. Barrett, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenqi Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William B Horton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Anesthesiology. 2008 Jul;109(1):14-24. doi: 10.1097/ALN.0b013e31817dced3.</citation>
    <PMID>18580168</PMID>
  </reference>
  <reference>
    <citation>Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 Dec 13;414(6865):813-20.</citation>
    <PMID>11742414</PMID>
  </reference>
  <reference>
    <citation>Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545. Review.</citation>
    <PMID>21030723</PMID>
  </reference>
  <reference>
    <citation>Brouwers O, Niessen PM, Haenen G, Miyata T, Brownlee M, Stehouwer CD, De Mey JG, Schalkwijk CG. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia. 2010 May;53(5):989-1000. doi: 10.1007/s00125-010-1677-0. Epub 2010 Feb 26.</citation>
    <PMID>20186387</PMID>
  </reference>
  <reference>
    <citation>Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002 Sep 3;106(10):1211-8.</citation>
    <PMID>12208795</PMID>
  </reference>
  <reference>
    <citation>Suzuki K, Watanabe K, Futami-Suda S, Yano H, Motoyama M, Matsumura N, Igari Y, Suzuki T, Nakano H, Oba K. The effects of postprandial glucose and insulin levels on postprandial endothelial function in subjects with normal glucose tolerance. Cardiovasc Diabetol. 2012 Aug 14;11:98. doi: 10.1186/1475-2840-11-98.</citation>
    <PMID>22891922</PMID>
  </reference>
  <reference>
    <citation>Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2346-50. doi: 10.2337/dc12-2469. Epub 2013 Apr 5.</citation>
    <PMID>23564922</PMID>
  </reference>
  <reference>
    <citation>Perkins JM, Joy NG, Tate DB, Davis SN. Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans. Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E168-76. doi: 10.1152/ajpendo.00064.2015. Epub 2015 May 26.</citation>
    <PMID>26015434</PMID>
  </reference>
  <reference>
    <citation>Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation. 1997 Apr 1;95(7):1783-90.</citation>
    <PMID>9107164</PMID>
  </reference>
  <reference>
    <citation>Cuypers MH, Kasanardjo JS, Polak BC. Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. Graefes Arch Clin Exp Ophthalmol. 2000 Dec;238(12):935-41.</citation>
    <PMID>11196354</PMID>
  </reference>
  <reference>
    <citation>Horová E, Mazoch J, Hiigertová J, Kvasnička J, Skrha J, Soupal J, Prázný M. Acute hyperglycemia does not impair microvascular reactivity and endothelial function during hyperinsulinemic isoglycemic and hyperglycemic clamp in type 1 diabetic patients. Exp Diabetes Res. 2012;2012:851487. doi: 10.1155/2012/851487. Epub 2012 Jan 4.</citation>
    <PMID>22262970</PMID>
  </reference>
  <reference>
    <citation>Burgansky-Eliash Z, Barak A, Barash H, Nelson DA, Pupko O, Lowenstein A, Grinvald A, Rubinstein A. Increased retinal blood flow velocity in patients with early diabetes mellitus. Retina. 2012 Jan;32(1):112-9. doi: 10.1097/IAE.0b013e31821ba2c4.</citation>
    <PMID>21878846</PMID>
  </reference>
  <reference>
    <citation>Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes. 1997 Sep;46(9):1381-8.</citation>
    <PMID>9287035</PMID>
  </reference>
  <reference>
    <citation>Chai W, Zhang X, Barrett EJ, Liu Z. Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance. Diabetes. 2014 Aug;63(8):2788-99. doi: 10.2337/db13-1597. Epub 2014 Mar 21.</citation>
    <PMID>24658303</PMID>
  </reference>
  <reference>
    <citation>Vincent MA, Dawson D, Clark AD, Lindner JR, Rattigan S, Clark MG, Barrett EJ. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes. 2002 Jan;51(1):42-8.</citation>
    <PMID>11756321</PMID>
  </reference>
  <reference>
    <citation>Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42.</citation>
    <PMID>16644702</PMID>
  </reference>
  <reference>
    <citation>Clerk LH, Vincent MA, Barrett EJ, Lankford MF, Lindner JR. Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition. Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1804-9. Epub 2007 Oct 2.</citation>
    <PMID>17911341</PMID>
  </reference>
  <reference>
    <citation>Jahn LA, Hartline L, Rao N, Logan B, Kim JJ, Aylor K, Gan LM, Westergren HU, Barrett EJ. Insulin Enhances Endothelial Function Throughout the Arterial Tree in Healthy But Not Metabolic Syndrome Subjects. J Clin Endocrinol Metab. 2016 Mar;101(3):1198-206. doi: 10.1210/jc.2015-3293. Epub 2016 Jan 12.</citation>
    <PMID>26756115</PMID>
  </reference>
  <reference>
    <citation>Inyard AC, Chong DG, Klibanov AL, Barrett EJ. Muscle contraction, but not insulin, increases microvascular blood volume in the presence of free fatty acid-induced insulin resistance. Diabetes. 2009 Nov;58(11):2457-63. doi: 10.2337/db08-1077. Epub 2009 Aug 12.</citation>
    <PMID>19675134</PMID>
  </reference>
  <reference>
    <citation>Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab. 2011 Feb;96(2):438-46. doi: 10.1210/jc.2010-1174. Epub 2010 Nov 3.</citation>
    <PMID>21047922</PMID>
  </reference>
  <reference>
    <citation>Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia. 2000 May;43(5):571-5.</citation>
    <PMID>10855531</PMID>
  </reference>
  <reference>
    <citation>Glaser N, Ngo C, Anderson S, Yuen N, Trifu A, O'Donnell M. Effects of hyperglycemia and effects of ketosis on cerebral perfusion, cerebral water distribution, and cerebral metabolism. Diabetes. 2012 Jul;61(7):1831-7. doi: 10.2337/db11-1286. Epub 2012 Apr 12.</citation>
    <PMID>22498698</PMID>
  </reference>
  <reference>
    <citation>Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998 Feb 10;97(5):473-83.</citation>
    <PMID>9490243</PMID>
  </reference>
  <reference>
    <citation>Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011 Jul;34(7):1634-8. doi: 10.2337/dc10-2345. Epub 2011 May 26.</citation>
    <PMID>21617098</PMID>
  </reference>
  <reference>
    <citation>Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation. 2005 Jul 12;112(2):179-84. Epub 2005 Jul 5.</citation>
    <PMID>15998667</PMID>
  </reference>
  <reference>
    <citation>Abdelmoneim SS, Hagen ME, Mendrick E, Pattan V, Wong B, Norby B, Roberson T, Szydel T, Basu R, Basu A, Mulvagh SL. Acute hyperglycemia reduces myocardial blood flow reserve and the magnitude of reduction is associated with insulin resistance: a study in nondiabetic humans using contrast echocardiography. Heart Vessels. 2013 Nov;28(6):757-68. doi: 10.1007/s00380-012-0305-y. Epub 2012 Nov 23.</citation>
    <PMID>23180239</PMID>
  </reference>
  <reference>
    <citation>Eggleston EM, Jahn LA, Barrett EJ. Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake. Diabetes. 2007 Dec;56(12):2958-63. Epub 2007 Aug 24.</citation>
    <PMID>17720897</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23.</citation>
    <PMID>382871</PMID>
  </reference>
  <reference>
    <citation>Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, Panza JA. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999 Aug 24;100(8):820-5.</citation>
    <PMID>10458717</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Eugene Barrett</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

